Studies to validate novel inhibitors of TYK2 kinase as anti-cancer therapeutics

验证新型 TYK2 激酶抑制剂作为抗癌疗法的研究

• 批准号: 132038
• 金额: $ 17.81万
• 依托单位: SAREUM LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132038
• 关键词: Studies; validate; novel; inhibitors; TYK2

The enzyme TYK2 has been shown to be a key therapeutic target in a rare type of leukaemia, T-ALL, which predominantly affects young adults. Sareum has discovered a novel series of selective inhibitors of TYK2, and have shown that they can prevent T-ALL cells from proliferating by causing programmed cell death. The aim of this feasibility study is to assess more compounds against additional T-ALL cell lines and to develop a broader understanding of the biology connecting T-ALL and TYK2. If the project is successful it would warrant further investment in a full lead optimisation programme to develop candidate molecules for clinical trials in patients.

TYK 2酶已被证明是一种罕见类型的白血病T-ALL的关键治疗靶点，这种白血病主要影响年轻人。Sareum发现了一系列新的TYK 2选择性抑制剂，并表明它们可以通过引起程序性细胞死亡来阻止T-ALL细胞增殖。这项可行性研究的目的是评估更多化合物对其他T-ALL细胞系的作用，并对T-ALL和TYK 2之间的生物学联系有更广泛的了解。如果该项目成功，将保证进一步投资于一个完整的先导优化计划，以开发用于患者临床试验的候选分子。